The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis

Cheryl Cero, Maria Razzoli, Ruijun Han, Bhavani Shankar Sahu, Jessica Patricelli, Zeng Kui Guo, Nathan A. Zaidman, John M. Miles, Scott M. O'Grady, Alessandro Bartolomucci

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives Obesity is characterized by excessive fat mass and is associated with serious diseases such as type 2 diabetes. Targeting excess fat mass by sustained lipolysis has been a major challenge for anti-obesity therapies due to unwanted side effects. TLQP-21, a neuropeptide encoded by the pro-peptide VGF (non-acronymic), that binds the complement 3a receptor 1 (C3aR1) on the adipocyte membrane, is emerging as a novel modulator of adipocyte functions and a potential target for obesity-associated diseases. The molecular mechanism is still largely uncharacterized. Methods We used a combination of pharmacological and genetic gain and loss of function approaches. 3T3-L1 and mature murine adipocytes were used for in vitro experiments. Chronic in vivo experiments were conducted on diet-induced obese wild type, β1, β2, β3-adrenergic receptor (AR) deficient and C3aR1 knockout mice. Acute in vivo lipolysis experiments were conducted on Sprague Dawley rats. Results We demonstrated that TLQP-21 does not possess lipolytic properties per se. Rather, it enhances β-AR activation-induced lipolysis by a mechanism requiring Ca2+ mobilization and ERK activation of Hormone Sensitive Lipase (HSL). TLQP-21 acutely potentiated isoproterenol-induced lipolysis in vivo. Finally, chronic peripheral TLQP-21 treatment decreases body weight and fat mass in diet induced obese mice by a mechanism involving β-adrenergic and C3a receptor activation without associated adverse metabolic effects. Conclusions In conclusion, our data identify an alternative pathway modulating lipolysis that could be targeted to diminish fat mass in obesity without the side effects typically observed when using potent pro-lipolytic molecules.

Original languageEnglish (US)
Pages (from-to)148-158
Number of pages11
JournalMolecular Metabolism
Volume6
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Lipolysis
Neuropeptides
Adrenergic Agents
Obesity
Complement C3a
Adipocytes
Adrenergic Receptors
Complement Receptors
Fats
Diet
Sterol Esterase
Obese Mice
Isoproterenol
Knockout Mice
Type 2 Diabetes Mellitus
Sprague Dawley Rats
Adipose Tissue
Body Weight
Pharmacology
Membranes

Keywords

  • Adipocyte
  • Ca
  • Complement 3a receptor
  • Isoproterenol
  • MAPK/ERK
  • VGF
  • β-AR

ASJC Scopus subject areas

  • Molecular Biology
  • Cell Biology

Cite this

Cero, C., Razzoli, M., Han, R., Sahu, B. S., Patricelli, J., Guo, Z. K., ... Bartolomucci, A. (2017). The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis. Molecular Metabolism, 6(1), 148-158. https://doi.org/10.1016/j.molmet.2016.10.005

The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis. / Cero, Cheryl; Razzoli, Maria; Han, Ruijun; Sahu, Bhavani Shankar; Patricelli, Jessica; Guo, Zeng Kui; Zaidman, Nathan A.; Miles, John M.; O'Grady, Scott M.; Bartolomucci, Alessandro.

In: Molecular Metabolism, Vol. 6, No. 1, 01.01.2017, p. 148-158.

Research output: Contribution to journalArticle

Cero, C, Razzoli, M, Han, R, Sahu, BS, Patricelli, J, Guo, ZK, Zaidman, NA, Miles, JM, O'Grady, SM & Bartolomucci, A 2017, 'The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis', Molecular Metabolism, vol. 6, no. 1, pp. 148-158. https://doi.org/10.1016/j.molmet.2016.10.005
Cero, Cheryl ; Razzoli, Maria ; Han, Ruijun ; Sahu, Bhavani Shankar ; Patricelli, Jessica ; Guo, Zeng Kui ; Zaidman, Nathan A. ; Miles, John M. ; O'Grady, Scott M. ; Bartolomucci, Alessandro. / The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis. In: Molecular Metabolism. 2017 ; Vol. 6, No. 1. pp. 148-158.
@article{5495e50d8b7742d394bea0af98380156,
title = "The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis",
abstract = "Objectives Obesity is characterized by excessive fat mass and is associated with serious diseases such as type 2 diabetes. Targeting excess fat mass by sustained lipolysis has been a major challenge for anti-obesity therapies due to unwanted side effects. TLQP-21, a neuropeptide encoded by the pro-peptide VGF (non-acronymic), that binds the complement 3a receptor 1 (C3aR1) on the adipocyte membrane, is emerging as a novel modulator of adipocyte functions and a potential target for obesity-associated diseases. The molecular mechanism is still largely uncharacterized. Methods We used a combination of pharmacological and genetic gain and loss of function approaches. 3T3-L1 and mature murine adipocytes were used for in vitro experiments. Chronic in vivo experiments were conducted on diet-induced obese wild type, β1, β2, β3-adrenergic receptor (AR) deficient and C3aR1 knockout mice. Acute in vivo lipolysis experiments were conducted on Sprague Dawley rats. Results We demonstrated that TLQP-21 does not possess lipolytic properties per se. Rather, it enhances β-AR activation-induced lipolysis by a mechanism requiring Ca2+ mobilization and ERK activation of Hormone Sensitive Lipase (HSL). TLQP-21 acutely potentiated isoproterenol-induced lipolysis in vivo. Finally, chronic peripheral TLQP-21 treatment decreases body weight and fat mass in diet induced obese mice by a mechanism involving β-adrenergic and C3a receptor activation without associated adverse metabolic effects. Conclusions In conclusion, our data identify an alternative pathway modulating lipolysis that could be targeted to diminish fat mass in obesity without the side effects typically observed when using potent pro-lipolytic molecules.",
keywords = "Adipocyte, Ca, Complement 3a receptor, Isoproterenol, MAPK/ERK, VGF, β-AR",
author = "Cheryl Cero and Maria Razzoli and Ruijun Han and Sahu, {Bhavani Shankar} and Jessica Patricelli and Guo, {Zeng Kui} and Zaidman, {Nathan A.} and Miles, {John M.} and O'Grady, {Scott M.} and Alessandro Bartolomucci",
year = "2017",
month = "1",
day = "1",
doi = "10.1016/j.molmet.2016.10.005",
language = "English (US)",
volume = "6",
pages = "148--158",
journal = "Molecular Metabolism",
issn = "2212-8778",
publisher = "Elsevier GmbH",
number = "1",

}

TY - JOUR

T1 - The neuropeptide TLQP-21 opposes obesity via C3aR1-mediated enhancement of adrenergic-induced lipolysis

AU - Cero, Cheryl

AU - Razzoli, Maria

AU - Han, Ruijun

AU - Sahu, Bhavani Shankar

AU - Patricelli, Jessica

AU - Guo, Zeng Kui

AU - Zaidman, Nathan A.

AU - Miles, John M.

AU - O'Grady, Scott M.

AU - Bartolomucci, Alessandro

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Objectives Obesity is characterized by excessive fat mass and is associated with serious diseases such as type 2 diabetes. Targeting excess fat mass by sustained lipolysis has been a major challenge for anti-obesity therapies due to unwanted side effects. TLQP-21, a neuropeptide encoded by the pro-peptide VGF (non-acronymic), that binds the complement 3a receptor 1 (C3aR1) on the adipocyte membrane, is emerging as a novel modulator of adipocyte functions and a potential target for obesity-associated diseases. The molecular mechanism is still largely uncharacterized. Methods We used a combination of pharmacological and genetic gain and loss of function approaches. 3T3-L1 and mature murine adipocytes were used for in vitro experiments. Chronic in vivo experiments were conducted on diet-induced obese wild type, β1, β2, β3-adrenergic receptor (AR) deficient and C3aR1 knockout mice. Acute in vivo lipolysis experiments were conducted on Sprague Dawley rats. Results We demonstrated that TLQP-21 does not possess lipolytic properties per se. Rather, it enhances β-AR activation-induced lipolysis by a mechanism requiring Ca2+ mobilization and ERK activation of Hormone Sensitive Lipase (HSL). TLQP-21 acutely potentiated isoproterenol-induced lipolysis in vivo. Finally, chronic peripheral TLQP-21 treatment decreases body weight and fat mass in diet induced obese mice by a mechanism involving β-adrenergic and C3a receptor activation without associated adverse metabolic effects. Conclusions In conclusion, our data identify an alternative pathway modulating lipolysis that could be targeted to diminish fat mass in obesity without the side effects typically observed when using potent pro-lipolytic molecules.

AB - Objectives Obesity is characterized by excessive fat mass and is associated with serious diseases such as type 2 diabetes. Targeting excess fat mass by sustained lipolysis has been a major challenge for anti-obesity therapies due to unwanted side effects. TLQP-21, a neuropeptide encoded by the pro-peptide VGF (non-acronymic), that binds the complement 3a receptor 1 (C3aR1) on the adipocyte membrane, is emerging as a novel modulator of adipocyte functions and a potential target for obesity-associated diseases. The molecular mechanism is still largely uncharacterized. Methods We used a combination of pharmacological and genetic gain and loss of function approaches. 3T3-L1 and mature murine adipocytes were used for in vitro experiments. Chronic in vivo experiments were conducted on diet-induced obese wild type, β1, β2, β3-adrenergic receptor (AR) deficient and C3aR1 knockout mice. Acute in vivo lipolysis experiments were conducted on Sprague Dawley rats. Results We demonstrated that TLQP-21 does not possess lipolytic properties per se. Rather, it enhances β-AR activation-induced lipolysis by a mechanism requiring Ca2+ mobilization and ERK activation of Hormone Sensitive Lipase (HSL). TLQP-21 acutely potentiated isoproterenol-induced lipolysis in vivo. Finally, chronic peripheral TLQP-21 treatment decreases body weight and fat mass in diet induced obese mice by a mechanism involving β-adrenergic and C3a receptor activation without associated adverse metabolic effects. Conclusions In conclusion, our data identify an alternative pathway modulating lipolysis that could be targeted to diminish fat mass in obesity without the side effects typically observed when using potent pro-lipolytic molecules.

KW - Adipocyte

KW - Ca

KW - Complement 3a receptor

KW - Isoproterenol

KW - MAPK/ERK

KW - VGF

KW - β-AR

UR - http://www.scopus.com/inward/record.url?scp=85008626281&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85008626281&partnerID=8YFLogxK

U2 - 10.1016/j.molmet.2016.10.005

DO - 10.1016/j.molmet.2016.10.005

M3 - Article

AN - SCOPUS:85008626281

VL - 6

SP - 148

EP - 158

JO - Molecular Metabolism

JF - Molecular Metabolism

SN - 2212-8778

IS - 1

ER -